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KEY POINTS
 Large interspecies and interindividual variability can be found in the pharmacokinetics of
antifungal drugs in birds, which can significantly affect drug safety and efficacy.
 The absorption of antifungals is affected by numerous factors, including drug formulation
and gastrointestinal anatomy and physiology.
 New antifungal drug delivery systems enhance drug stability, reduce off-target side
effects, prolong residence time in the blood, and improve drug efficacy, and should there-
fore be considered in the treatment of mycoses.
 Nebulization seems to be a promising method to deliver antifungals in the respiratory tract
of birds; however, therapeutic output is influenced by drug formulation and nebulizer type.INTRODUCTION
The early diagnosis of systemic fungal diseases in birds, especially aspergillosis,
remains challenging because the clinical signs are usually nonspecific and there still
is no single reliable noninvasive diagnostic test available in birds.1–3 Consequently,
antifungal therapy is frequently administered empirically for presumptive invasive
fungal infections in these patients without a definitive diagnosis being made. However,
different factors need to be considered in the rational drug selection of antifungal
therapy. First, the selected antifungal drug must be able to penetrate the center of
infection in a concentration to which the fungus is susceptible. However, fungi, inDisclosure Statement: The authors have nothing to disclose.
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Antonissen & Martel356contrast with bacteria, are eukaryotes, and consequently most antifungal agents are
also toxic to the eukaryotic host cells. Therefore, taking into account their (often nar-
row) therapeutic index, no perfect antifungal agent exists. Nevertheless, in the last de-
cades, newer and less toxic antifungals, including the azoles and echinocandins, have
been developed for use in human medicine. Aside from the chemical structure, the
impact of antifungal drug formulation and route of administration on treatment safety
and efficacy have been investigated as well.4
Because knowledge of avian antifungal treatment is limited, treatment protocols are
often developed empirically, based on case reports, or extrapolated from humans or
other animal species. Because of the narrow therapeutic index, the dosing of anti-
fungal drugs should be done carefully, with dose extrapolation preferably based on
more advanced allometric and physiologically based pharmacokinetic (PK) modeling.5
In avian medicine, different antifungal agents are being used, but most of these
substances have not been approved for administration in birds.6 However, recently
(2014) the first antifungal product (itraconazole 10 mg/mL oral solution; Fungitraxx,
Avimedical, Hengelo, The Netherlands) was registered for ornamental birds in Europe
(EMA/698698/2013). The purpose of this review is to describe the interrelation of anti-
fungal drug formulation, administration route, therapeutic–toxic range, and treatment
outcome in fungal diseases, with a particular emphasis on aspergillosis in companion
birds.MECHANISM OF ACTION
In general, the main targets for antifungal drug development are cell wall polymer (glu-
cans, chitin, mannoproteins), cell membrane (especially ergosterol) biosynthesis, DNA
and protein synthesis (topoisomerases, nucleases, elongation factors and myristoyla-
tion), and signal transduction pathways (protein kinases and protein phosphatases).7,8
The 3 major groups of antifungal agents in clinical use, that is, polyenes, azole deriv-
atives, and allylamines, all owe their antifungal activities to the inhibition of synthesis or
direct interaction with ergosterol (the predominant component of the fungal cell
membrane).8,9
Amphotericin B and nystatin are polyene macrolides that act by binding to ergos-
terol. This binding alters the membrane permeability, causing leakage of sodium, po-
tassium, and hydrogen ions, which eventually leads to cell death. Polyenes have a
broad antifungal spectrum, including a variety of yeasts (eg, Candida spp) and molds
(eg, Aspergillus spp).9
Azoles inhibit the enzyme cytochrome P450-dependent 14-a-sterol demethylase,
which is required for the conversion of lanosterol to ergosterol. Exposed fungi become
depleted of ergosterol and accumulate 14-a-methylated sterols. This action causes
disruption of membrane structure and function, thereby inhibiting fungal growth.9,10
Azoles are classified as imidazoles (including clotrimazole, miconazole, enilconazole,
and ketoconazole) or triazoles (including itraconazole, fluconazole, and voriconazole)
based on possessing 2 or 3 nitrogen atoms in the 5-membered azole ring, respec-
tively. Depending on the particular compound, azole antifungal agents have fungistatic
and broad-spectrum activity against most yeasts and filamentous fungi.9 With the
exception of voriconazole, azoles are known to be fungistatic at the doses used in
birds and need several days to reach steady-state concentrations.11
Finally, allylamines (eg, terbinafine) act bya reversible, noncompetitive inhibitionof the
squalene epoxidase, a key enzyme in the cyclization of squalene to lanosterol, resulting
in an ergosterol depletion and squalene accumulation. The antifungal spectrum of terbi-
nafine includes yeast (fungistatic) as well as dermatophytes andmolds (fungicidal).6,9,12
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The clinical use of amphotericin B has been associated with a dose-dependent
nephrotoxicity in mammals. Because amphotericin B binds to mammalian sterols,
including cholesterol, renal toxicity is related to binding of the drug to the sterol rich
cell membranes in kidney tubules. As a result, amphotericin B affects the ionic perme-
ability of the renal brush border cells, releasing mediators that cause an abrupt
decrease in renal blood flow. However, no evidence of nephrotoxicity has been
observed in birds, which might be associated with the shorter elimination half-life
(T1/2el) in birds compared with mammals after intravenous (IV) administration.
11,13
Nevertheless, clinicians are advised to monitor the renal function of their avian
patients.
The relative toxicity of azoles depends on the specificity for binding to the fungal cy-
tochrome P450 enzyme, instead of the avian/mammalian cytochrome P450 enzymes.
The most common adverse side effects associated with azole administration in birds
are gastrointestinal (GI) signs, such as anorexia and vomiting, and alterations in liver
function.14,15 In general itraconazole, is well-tolerated; however, caution should be
used when considering the use of this drug in African or timneh gray parrots, because
they are more sensitive to itraconazole present in the form of distinct anorexia and
depression.6,11 Remarkably, PK studies explaining this higher sensitivity in African
or timneh gray parrots are still lacking (Table 1). The apparent sensitivity to azoles
experienced by different bird species may be explained in part by the drug’s PK
and metabolism. In humans, cytochrome P450 isoenzyme CYP2C19 genotypic poly-
morphism has been linked to differential sensitivity to voriconazole toxicity.16,17
Although undocumented in avian species, similar polymorphisms could be respon-
sible for the wide variability in avian voriconazole PK properties. After a single oral
administration of voriconazole, a 4 to 5 times longer T1/2el was observed in pigeons
(Columba livia domestica) and African penguins (Spheniscus demersus), compared
with Hispaniolan Amazon parrots (Amazona ventralis), timneh gray parrots (Psittacus
erithacus timneh), mallard ducks (Anas platyrhynchos), and red-tailed hawks (Buteo
jamaicensis; Table 2).18–23 This prolonged T1/2el in pigeons and penguins presents a
potential for drug accumulation with extended dosing and toxicity. After oral adminis-
tration of voriconazole (10 and 20 mg/kg body weight [BW] twice a day) to pigeons,
Beernaert and colleagues19 observed hepatic changes, such as hepatomegaly and
miliary hepatic necrosis and, on histology, vacuolization up to apoptosis of hepato-
cytes and heterophilic and lymphocytic infiltration. Similarly, Hyatt and colleagues24
demonstrated signs indicative of toxicity in multiple penguin species after adminis-
tering voriconazole (6.1–22.2 mg/kg BW once or twice a day), which ranged in severity
and included anorexia, lethargy, weakness, change in mentation, ataxia, paresis,
apparent vision changes, seizurelike activity, and generalized seizures. The toxicity
and efficacy of all azole derivatives can furthermore be influenced by drug–drug
interactions that are based on the mechanism of action of these drugs being
potent cytochrome P450 inhibitors. Consequently, caution should be taken when
azoles are coadministered with other drugs, such as midazolam, enrofloxacin, and
clindamycin.6,24
Finally, terbinafine is generally associated with a low index of toxicity and few
adverse effects. In humans, only mild GI toxicity and hepatobiliary dysfunction are
reported. In red-tailed hawks, oral administration of a high dose of terbinafine
(120 mg/kg BW) was furthermore demonstrated to induce regurgitation.25 Anecdot-
ally, some mild GI toxicity and hepatobiliary dysfunction were observed in some psit-
tacine species including an African gray parrot, a blue-fronted Amazon parrot
Table 1
Plasma and lung itraconazole and hydroxyitraconazole concentrations after single bolus and steady-state pharmacokinetic studies of itraconazole in
different bird species
Animal Species BW (g)
Dosage
Itraconazole
(mg/kg BW) Drug Formulation
Frequency of
Administration Feed
Itraconazole (ng/mL)
Hydroxyitraconazole
(ng/mL)
ReferenceCmin Cmax Clung Cmin Cmax Clung
PK single
bolus
Pigeon 488 10.3 ITRA-LAC Single bolus — — 1130 250 — — — Lumeij
et al,55
1995
5 ITRA-LAC 1 orange
juice
Single bolus No — 100–200a 339 — — — Orosz
et al,53
1995
5 ITRA-LAC 1 orange
juice 1 0.1 N HCl
Single bolus Yes — 100–200a 476 — — —
Blue-fronted
Amazon
parrot
306–424 5 ITRA-LAC 1 orange
juice 1 0.1 N HCl
Single bolus Yes — 1743 — — 247 — Orosz
et al,57
1996
10 ITRA-LAC 1 orange
juice 1 0.1 N HCl
Single bolus Yes — 2312 — — 1976 —
Red-tailed
hawks
5 ITRA-LAC 1 orange
juice 1 0.1 N HCl
Single bolus Yes — 50–300a — — 50–150a — Jones
et al,56
2000
10 ITRA-LAC 1 orange
juice 1 0.1 N HCl
Single bolus Yes — 250–300a — — 200–250a —
Mallard Duck 979–1442 20 ITRA-LAC 1 orange
juice 1 0.1 N HCl
Single bolus Yes — 1070 730 — 340 275 Tell
et al,49
2005
20 ITRA-CD Single bolus Yes — 1350 796 — 270 313
Black-footed
penguin
2600–4400 7 ITRA-GEN Single bolus Yes — 350 — — — — Smith
et al,80
2010
7 ITRA-CD Single bolus Yes — 750 — — — —
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PK at
steady
state
Pigeon 488 10.3 ITRA-LAC QID, 3 d — — 3875 — — — — Lumeij
et al,55
1995
5 ITRA-LAC 1 orange
juice
SID, 14 d No — 100–200a 250 — — 3206 Orosz
et al,53
1995
5 ITRA-LAC 1 orange
juice 1 0.1 N HCl
SID, 14 d Yes — 500–600a 359 — — 79,876
Blue-fronted
Amazon
parrot
306–424 5 ITRA-LAC 1 orange
juice 1 0.1 N HCl
SID, 14 d Yes — 1437 — 197 309 — Orosz
et al,57
1996
10 ITRA-LAC 1 orange
juice 1 0.1 N HCl
SID, 14 d Yes — 3434 — 92 1976 —
Red-tailed
hawks
5 ITRA-LAC 1 orange
juice 1 0.1 N HCl
SID, 14 d Yes — 300–360a 2598 — 150–360a 1750 Jones
et al,56
2000
10 ITRA-LAC 1 orange
juice 1 0.1 N HCl
SID, 14 d Yes — 150–500a 2941 — 120–480a 2113
Humboldt
penguin
3420–5760 6 ITRA-GEN SID, 14 d Yes — ND — 30 248 — Bunting
et al,51
2009
12 ITRA-GEN SID, 14 d Yes — 52 — 55 331 —
6 ITRA-CD SID, 14 d Yes — 10–100a — 166 829 —
12 ITRA-CD SID, 14 d Yes — 175 — 525 2335 —
7 ITRA-CD BID, 14 d Yes 104 262 — 673 994 —
Abbreviations: BID, twice a day; BW, bodyweight; Clung, concentration in lung; Cmax, maximum plasma concentration; Cmin, minimal plasma concentration in mul-
tiple doses PK; ITRA-CD, itraconazole 1 hydroxypropyl-b-cyclodextrin; ITRA-GEN, generic bulk compounded itraconazole powder; ITRA-LAC, itraconazole-coated
lactose granules; ND, not detected; PK, pharmacokinetic; QID, 4 times a day; SID, once a day.
a Estimated concentration based on graph or table in original study.
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Tab 2
PK aracteristics of voriconazole after single bolus and multiples doses administration in different bird species
Animal
Species BW (g)
Dosage
Voriconazole
(mg/kg BW)
Frequency of
Administration Feed F (%)
Cmin
(ng/mL) Tmax (h)
Cmax
(ng/mL)
Vd (IV)
Vd/F
(Oral)
(mL/kg)
T1/2el
(h)
Cl (IV)
Cl/F (Oral)
(mL/h$kg)
Clung
(ng/g)
Cliver
(ng/g) Reference
PK
b lus
Chicken:
layers
740–1110 10b Single No 100 — — 7400 1681 1.99 586 — — Burhenne
et al,59
2008
Pigeon 400–500 2.5a Single Yes 100 — — — 1110 6.62 120 — — Beernaert
et al,19
2009
5a Single Yes 100 — — — 1410 11.33 86 — —
10a Single Yes 100 — — 5576 1790 16.25 76 — —
Mallard
duck
1060  110 10a Single No 100 — — — 1440 1.34 530 ND ND Kline
et al,22
2011
PK ral
b lus
Chicken:
layers
740–1106 5 Single No — — 0.83 350 — 1.35 — — — Burhenne
et al,59
2008
7.5 Single No — — 2.00 410 — 2.40 — — —
10 Single No — — 0.83 440 — 1.23 — — —
10 Single No 16 — 1.50 700 — — — — —
10 Single No 20 — 0.75 880 — 1.45 — — —
15 Single No — — 1.50 510 — 1.77 — — —
Pigeon 400–500 10b Single No 44 — 2.15 3317 2600 10.32 176 — — Beernaert
et al,19
2009
Japanese
quail
104–179 20 Single Yes — — 2.00 5800 1770 — — — — Tell
et al,60
2010
40b Single Yes — — 2.00 6900 6100 — — — —
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Hispaniolan
Amazon
parrot
260–320 12c Single No — — 1.00 2490 2054 0.90 1576 — — Guzman
et al,20
2010
24c Single No — — 2.00 5080 2349 1.25 1306 — —
Timneh
gray
parrot
290–339 6b Single — — — 2.00 540 3498 1.11 2185 — — Flammer
et al,21
2008
12b Single — — — 4.00 1890 2634 1.59 1151 — —
12c Single — — — 2.00 3020 1051 1.07 679 — —
18c Single — — — 2.00 5670 1200 1.59 521 — —
Mallard
duck
1060  110 10b Single No 61 — 0.77 3940 1504 — — ND ND Kline
et al,22
2011
10b Single Yes — — 1.50 7350 — 1.00 — ND 0.04–0.06
20b Single Yes — — 1.50 10,600 — 1.75 — ND-0.16 0.04–0.47
40b Single Yes — — 2.00 24,443 — 1.37 — ND 0.06–0.17
Red-tailed
hawks
926–1410 15b Single No — — 2.29 7230 1180 2.04 431 — — Parsley
et al,23
2017
15b Single Yes — — 4.86 6180 1349 2.29 485 — —
African
penguin
2200–3400 5c Single No — — 0.40 1890 — 10.92 — — — Hyatt
et al,18
2017
Multiple
doses PK
Chicken:
layers
1030–1770 10b SID, 10 d Yes — — 1.00 280 — — — ND 140 Burhenne
et al,59
2008
10b SID, 20 d Yes — — 3.00 1590 — — — 765 5360
10b SID, 30 d Yes — — 3.00 400 — — — 255 817
Pigeon 400–500 10b SID, 3 d Yes — 134–418 2.00 2417–3683 — — — ND - 598 — Beernaert
et al,19
2009
20b SID, 10 d Yes — 154–1516 2.00 5352–9183 — — — — —
10b BID, 4 d Yes — ND-3500d 2.00 3350–8000d — 1.60 — 100 —
20b BID, 4 d Yes — 5847 2.00 15,876 — — — ND-1241 —
(continued on next page)
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Table 2
(continued )
Animal
Species BW (g)
Dosage
Voriconazole
(mg/kg BW)
Frequency of
Administration Feed F (%)
Cmin
(ng/mL) Tmax (h)
Cmax
(ng/mL)
Vd (IV)
Vd/F
(Oral)
(mL/kg)
T1/2el
(h)
Cl (IV)
Cl/F (Oral)
(mL/h$kg)
Clung
(ng/g)
Cliver
(ng/g) Reference
Hispaniolan
Amazon
parrot
260–320 18c TID, 11 d Yes — — 2.00 790 — 1.29 — — — Guzman
et al,20
2010
Timneh
gray
parrot
290–339 18c BID, 9 d — — 58–63 — 2600–2800 — — — — — Flammer
et al,21
2008
Mallard
duck
1060  110 20b SID, 21 d No — — 1.00 9960 904 0.72 — ND-0.19 ND-0.06 Kline
et al,22
2011
20b SID, 21 d Yes — — 1.08 8090 1624 1.11 — ND ND-0.12
African
penguin
220–3400 5b SID, 8 d Yes — 500–3250 1.53 3640–5640 1193e — 64e — — Hyatt
et al,18
2017
Abbreviations: BID, twice a day; BW, bodyweight; Cl or Cl/F, clearance; Cliver, voriconazole concentration in liver; Clung, voriconazole concentration in lung; Cmax, maximum
plasma concentration; Cmin, minimal plasma voriconazole concentration in multiple doses PK; F, absolute bioavailability; IV, intravenous; ND, not detected; PK, pharmaco-
kinetic; SID, once a day; T1/2el, elimination half-life; TID, 3 times a day; Tmax, time point of maximum plasma concentration; Vd or Vd/F, volume of distribution.
a Voriconazole sulfobutylether-b-cyclodextrin was suspended in 0.9% NaCl.
b Water.
c Commercial suspending agent.
d Estimated concentration based on graph in original study.
e Calculated based on average bodyweight.
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363Antifungal Therapy in Birds(Amazona aestiva), and a Senegal parrot (Poicephalus senegalus) after long-term
administration of terbinafine (10–15 mg/kg BW, twice a day) alone or in combination
with itraconazole or voriconazole (van Zeeland, personal communication, 2017).
DRUG RESISTANCE
Antifungal susceptibility testing is a useful tool to provide information to clinicians to
help guide therapy. The European Committee on Antimicrobial Susceptibility Testing
and the Clinical and Laboratory Standards Institute have developed a standardized
in vitro antifungal susceptibility testing method for yeasts and molds, whereby the
minimum inhibitory concentration (MIC) is measured and referenced to a clinical
breakpoint. However, in birds, the interpretation of the MICs of different antifungal
agents remains uncertain, because of lack of correlation of in vitro resistance with
clinical outcome.26,27 Although information on antifungal resistance in avian medicine
is very limited, human medicine shows that antifungal resistance is increasing and is
an emerging threat to patient management and clinical success. Beernaert and
colleagues28 reported an acquired resistance of Aspergillus fumigatus strains, isolated
from companion and wild birds, to both itraconazole and voriconazole. However,
current in vitro antifungal susceptibility tests do not (yet) take the impact of drug
formulation into account. Consequently, interpretation of MICs of amphotericin B
against Aspergillus spp remains uncertain because of lack of correlation of in vitro
resistance with clinical outcome. For example, differences in PK characteristics
(eg, tissue concentration of free drug in the site of infection) or immunomodulating
properties between, for example, amphotericin B deoxycholate and liposomal ampho-
tericin B, might be more important determinants of outcome of amphotericin B-based
therapy than the MIC. In a murine model of disseminated invasive aspergillosis, treat-
ment with liposomal amphotericin B resulted in a better outcome than treatment with
amphotericin B deoxycholate, despite no differences in the MIC being observed be-
tween the drug formulations.27
DRUG FORMULATION
Several antifungal drugs are characterized by their insolubility in water at physiologic
pH, poor oral bioavailability, and limited formulation approaches. In addition, a narrow
therapeutic–toxic range and drug–drug interactions of systemic antifungal agents are
other major problems that compromise optimal treatment.29,30 Therefore, there is a
strong need to develop innovative drug formulations to address these issues.
In an attempt to decrease the intrinsic toxicity and enhance the efficacy of ampho-
tericin B, 3 lipid-associated formulations were developed and approved for use in hu-
man medicine in the 1990s, that is, amphotericin B lipid complex, liposomal
amphotericin B, and amphotericin B colloidal dispersion. Amphotericin B lipid com-
plex (Abelcet, Cephalon, Inc., Fraser, PA) forms ribbonlike particles of dimyristoyl
phosphatidyl choline and dimyristoyl phosphatidyl glycerol with amphotericin B; lipo-
somal amphotericin B (AmBisome, Gilead Sciences International Ltd., Cambridge,
UK; and Fungisome, Lifecare Innovations Pvt Ltd, Gurgaon, India) is a true unilamellar
liposome composed of a mixture of phosphatidyl choline:distearoyl:phosphatidylgly-
cerol:cholesterol; and amphotericin B colloidal dispersion (Amphotec of Amphocil,
Sequus Pharmaceuticals, Menlo Park, CA) is a formulation in which amphotericin B
is complexed to cholesterol sulfate resulting in the formation of disclike structures.
Knowledge based on in vitro and in vivo studies in rodents, dogs, and humans suggest
that these lipid formulations of amphotericin B generally have a slower onset of action,
because of the required dissociation of free amphotericin B from the lipid vehicle.
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take by the liver and spleen, and cause accumulation of the drug by the mononuclear
phagocyte system and at sites of capillary damage and inflammation. Consequently,
the PK characteristics of lipid-based amphotericin is strongly determined by its
physicochemical properties. Amphotericin B lipid complex is the largest compound
of the lipid preparations (diameter of 1600–11,000 nm), resulting in a fast recognition
in the blood by activated monocytes/macrophages, which subsequently transport the
drug to the site of infection, where phospholipases release the free drug. In addition,
this compound is sequestered to a high extent in the tissues of the mononuclear
phagocyte system (liver and spleen), including the lungs. This rapid and extensive dis-
tribution, predominantly to the liver, spleen, and lungs, is reflected in the PK charac-
teristics by a very large volume of distribution and a low area under the plasma
concentration time curve. Lung levels are considerably higher than those achieved
with other lipid-associated preparations and amphotericin B deoxycholate. The small
size of liposomal amphotericin B (diameter of 60–80 nm) and negative charge tend to
result in a prolonged circulation in plasma, because these compounds are not readily
recognized and taken up by the mononuclear phagocyte system. However, the clinical
relevance of these PK differences between liposomal amphotericin B and amphoter-
icin B lipid complex remains unknown. After IV infusion, amphotericin B colloidal
dispersion (disks of 122 nm diameter and 4 nm thickness) is rapidly removed from
the circulation by the mononuclear phagocyte system, predominantly by Kupffer cells
of the liver, and to a lesser extent in the spleen and bone marrow. These differences in
PK and pharmacodynamic characteristics are reflected in the dose recommendations
in human medicine: amphotericin B deoxycholate 0.25 to 1.5 mg/kg once a day,
amphotericin B lipid complex 5 mg/kg BW once a day, liposomal amphotericin B 1
to 5 mg/kg BW once a day, and amphotericin B colloidal dispersion 3 to 5 mg/kg
once a day.31 However, the impact of these differences in PK/pharmacodynamics
on clinical efficacy in birds is still unclear. Comparatively, amphotericin B deoxycho-
late is administered at a dose of 1 to 1.5 mg/kg BW 3 times a day to birds.3
In humans, the superior safety profile of lipid-associated formulations is character-
ized by decreased acute infusion-related reactions and dose-related nephrotoxicity,
allowing the administration of larger doses and therefore similar efficacy with fewer
administrations. In vitro studies and human clinical data suggest that amphotericin
B lipid complex and liposomal amphotericin B induce a Toll-like receptor 4 reaction
instead of a Toll-like receptor 2 reaction, as observed with amphotericin deoxycholate,
causing attenuation of the characteristic proinflammatory response. Unlike the other
lipid-associated amphotericin B preparations, the amphotericin B colloidal dispersion
is associated with a higher frequency of infusion-related reactions associated with an
inflammatory gene upregulation similar as amphotericin B deoxycholate. The patho-
physiology of amphotericin B–induced nephrotoxicity is associated with a vasocon-
strictive effect on the afferent renal arterioles, decreasing the glomerular filtration
rate and inducing tubular dysfunction. Complexation with lipids seems to stabilize
amphotericin B in a self-associated state so that it is not available to interact with
cholesterol in mammalian or avian cellular membranes, which is the presumed major
site of toxicity. Moreover, amphotericin B alone binds preferentially to low-density li-
poproteins and can be internalized into renal cells that express low-density lipoprotein
receptors, resulting in toxicity. Amphotericin B from lipid-associated formulations
binds preferentially to high-density lipoproteins, which reduces nephrotoxicity by
decreasing the uptake of amphotericin B by renal cells because of their low level of
high-density lipoprotein receptors.32 Recently, Phillips and colleagues33 demon-
strated that a single dose (3 mg/kg BW) of liposomal amphotericin B delivered by
Antifungal Therapy in Birds 365aerosol to healthy mallard ducks resulted in minimal systemic distribution of the drug
after administration, characterized by low plasma and kidney amphotericin B concen-
trations and no signs of drug-associated damage on histopathologic examination of
renal, hepatic, or cardiac tissue samples. Similarly, based on clinical examination
and plasma uric acid levels, no signs of nephrotoxicity were observed in a goliath her-
on (Ardea goliath) with a deep infection with Aspergillus species of its pectoral muscle
topically treated with liposomal amphotericin B (1.35 mg/kg, once a day) mixed with
sterile, water-soluble, gelatin lubricant for more than 1 month.34
Studies in mouse and rabbit models of fungal infection and human metaanalyses
have shown the liposomal formulation of amphotericin B to be at least as effective
as amphotericin B deoxycholate in improving survival and resolving the infection.35–37
After intratracheal aerosol administration of liposomal amphotericin B to healthy
mallard ducks, drug concentrations in pulmonary parenchyma reached above the tar-
geted MIC for avian isolates of Aspergillus species of 1 mg/mL.33 Although these lipid
formulations are reported to have excellent safety and efficacy, the high price of these
drugs may currently preclude their use in veterinary medicine compared with the con-
ventional form.
Among many new antifungal drug delivery systems currently under investigation,
nanoparticles (NPs) have emerged as an innovative and promising platform able to
enhance drug stability, reduce off-target side effects, prolong residence time in the
blood, and improve drug efficacy. NPs are characterized by their small particle size
ranging from 1 to 1000 nm.30 Liposomal amphotericin is the first and most successful
commercial NP of antifungal drugs in humans.38 NPs used in drug delivery can
be classified into phospholipid vesicles (eg, liposomes), nonphospholipid vesicles,
polymeric NPs, polymeric micelles, solid lipid NPs, nanostructured lipid carriers, nano-
emulsions, and dendrimers.30 For example, liposomal nystatin allowed the IV admin-
istration of nystatin, increased the maximum tolerated dose in mice from 4 to 16mg/kg
BW, and increased the survival rate of mice infected with Candida albicans.39 Itraco-
nazole incorporated into poly(lactide-co-glycolide) (PLGA) resulted in a sustained-
release formulation for IV administration with plasma itraconazole levels for more
than 3 times longer than the commercial formulation.40 PLGA containing voriconazole
was detectable in lungs until 5 to 7 days after pulmonary disposition in mice via an
inhalation chamber.41 Recently, Pardeike and colleagues42 demonstrated that nebu-
lized itraconazole-loaded nanostructured lipid carriers penetrate deeply into the lungs
and air sacs of a falcon, being a prerequisite for pulmonary treatment of aspergillosis.
Administration Route
The route of administration of antifungals will depend on the drug, available drug
formulation, condition of the bird, ability of the owner and/or veterinary staff to deliver
the drug, and the financial and emotional commitment of the bird’s owner. Taking into
account the narrow therapeutic–toxic range of all commercially available antifungal
drugs, selecting the most optimal route of administration of a certain compound, in
a certain patient, helps to decrease toxicity and to quickly establish effective local
drug concentration.
Systemic Treatment
Most systemic fungal infections require long-term therapy that often extends for
weeks to months.3,6 Treatment protocols should not merely include drugs for IV
administration because of problems related to maintaining a permeable venous
pathway for long periods of time in birds. Nevertheless, vascular access devices
have been suggested to be useful for cases that require long-term, frequent
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dominantly amphotericin B) in birds is only performed in rare cases, for example, in
the initial treatment of acute aspergillosis, or in severely debilitated birds. IV adminis-
tration should always be combined with an oral antifungal drug, which is often admin-
istered for at least several weeks to months.6 PK studies of IV-administered
amphotericin B deoxycholate in turkeys (Meleagris gallapavo), red-tailed hawks,
broad-winged hawks (Buteo platypterus), and great horned owls (Bubo virginianus)
have reported that the T1/2el for avian species is much shorter than that for mammals,
suggesting that twice daily dosing is appropriate.11,13 Amphotericin B can be admin-
istered IV under the form of amphotericin B deoxycholate or in a lipid-associated
formulation. Standardized electrolyte supplementation and fluid management
improve clinical amphotericin B efficacy by minimizing toxicity.44 Voriconazole and flu-
conazole have the advantage compared with amphotericin B that, in addition to an IV
formulation, an oral formulation is commercially available as well, rendering these
drugs suitable for long-term use in birds.45–47
Recently, Souza and colleagues48 assessed the efficacy of itraconazole, voricona-
zole and terbinafine containing implants in Japanese quails (Coturnix japonica). These
implants were administered subcutaneously over the dorsum and between the scap-
ulae. Targeted plasma terbinafine concentrations were achieved in some birds at
various time points; however, concentrations were inconsistent. Itraconazole and vor-
iconazole concentrations were also inconsistent and below the minimal MIC. Similarly,
after subcutaneous administration of 2 itraconazole controlled release gel formula-
tions, only very low or undetectable plasma and tissue concentrations of itraconazole
and hydroxyitraconazole were found.49 Consequently, the administration of an
impregnated subcutaneous implant is not (yet) an effective method to treat a fungal
infection in birds.
Oral dosing of antifungal drugs is the most common route of administration in sys-
temic fungal diseases. However, oral drug absorption is a complex process affected
by numerous factors associated with the drug’s formulation characteristics and the
GI anatomy and physiology of the target species.50 Bunting and colleagues51
demonstrated that the maximum itraconazole and hydroxyitraconazole plasma con-
centrations after oral administration of the commercially available itraconazole with
hydroxypropyl-b-cyclodextrin were much higher compared with generic bulk com-
pounded itraconazole powder in Humboldt penguins (see Table 1). In addition, fac-
tors such as GI pH and transit time are characterized by considerable variability
between and within types of birds. Many azoles are highly lipophilic and poorly wa-
ter soluble at a neutral pH; however, they are soluble in acidic solutions. The pH of
the crop and stomach of birds is considerably less acidic than the mammalian stom-
ach, possibly because of the rapid digestive transit time, which negatively affect
antifungal drug solubility and absorption.52 Further adding to the complexity of
absorption is the coadministration of food. Concurrent administration of itracona-
zole with an intracrop feed bolus and dissolving itraconazole-lactose granules in
0.1 N hydrochloric acid (HCl) before oral administration to pigeons (5 mg/kg BW,
once a day for 14 days) increased the maximum plasma concentration of itracona-
zole and the concentration of its metabolite hydroitraconazole in the lung
(see Table 1).53 The relative bioavailability of voriconazole administered orally
(20 mg/kg BW, once a day) in mallard ducks with a bolus of liquid feed was slightly
higher compared with birds that were not being fed at the time of drug administra-
tion (see Table 2).22 In contrast, in falcons, it was observed that, by administering
voriconazole in meat, the median peak plasma concentrations were reduced by
21% to 26%.54
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nazole concentrations after a single bolus and steady-state PK studies in different bird
species (see Table 1). Because of the extended time to reach steady state, in cases
of acute aspergillosis or in severely diseased birds, itraconazole should initially be
combined with amphotericin B (IV) or voriconazole (IV or by mouth) for 3 to 5 days.
In the different studies, steady-state concentrations after oral administration
were reached within 3 to 14 days.51,53,55–57 Steady-state plasma concentrations
itraconazole plus hydroxyitraconazole above the MIC of 500 to 1000 ng/mL were
achieved in pigeons, blue-fronted Amazon parrots, red-tailed hawks, and Humboldt
penguins administered itraconazole (see Table 1).28,51,53,55–57 Unfortunately, concen-
tration of itraconazole and its active metabolite in the lung and other target organs
were only measured in pigeons and red-tailed hawks.53,55,56 After oral administration
of itraconazole to pigeons and red-tailed hawks in a dosage of 5 mg/kg BW, once a
day for 14 days, the sum of the mean lung concentration of itraconazole and hydrox-
yitraconazole was above the MIC in both species, 3456 to 80,235 ng/g and 4348 ng/g,
respectively (see Table 1). However, a high interindividual variability of itraconazole
and hydroxyitraconazole concentrations was observed in all tissues.53,56 Based on
these studies, the following dosing regimens have been suggested for itraconazole:
pigeons, 6 to 26 mg/kg BW twice a day; blue-fronted Amazon parrot, 5 mg/kg BW
once a day; red-tailed hawks, 10 mg/kg once a day; and Humboldt penguins,
8.5 mg/kg twice a day or 20 mg/kg once a day.51,53,56,57 Recently, it was demon-
strated in rats that the oral bioavailability of an experimental liposomal formulation
of itraconazole-containing sodium deoxycholate was 1.67-fold higher than that of
the commercially available itraconazole formulation containing hydroxypropyl-
b-cyclodextrin.58 However, whether this new experimental liposomal formulation
can also improve the oral bioavailability of itraconazole in birds, and decrease the
high interindividual variability of itraconazole and hydroxyitraconazole concentrations
in the target organs, needs further investigation. In addition, an increased oral bioavail-
ability might also lower the GI toxicity of itraconazole; however, systemic toxicity
(eg, hepatotoxicity) might increase.
Voriconazole is increasingly used to treat invasive aspergillosis in birds, given the
broad antifungal spectrum, which includes molds (fungicidal) and yeasts (fungistatic),
and its fast bioavailability.6,19,22,59 Beernaert and colleagues45 demonstrated that
administering voriconazole (10 mg/kg BW twice a day) orally in pigeons reduced
clinical signs and eliminated A fumigatus in racing pigeons experimentally infected
with A fumigatus. Similarly, Tell and colleagues60 showed that oral administration of
voriconazole (20 and 40 mg/kg BW once a day) reduced mortality rate in Japanese
quails after experimental A fumigatus infection.
The clinical efficacy of voriconazole was also demonstrated in falcons with aspergil-
losis. Complete clinical resolution occurred in 70% of the birds, partial response in
25%, and 1 bird (5%) died during treatment.61 However, interspecies and interindi-
vidual variability in this drug’s PK profile necessitates species-specific PK studies.
The average oral voriconazole bioavailability for pigeons and mallard ducks, 44%
and 61%, respectively, is much higher compared with chickens, at 16% to 20%
(see Table 2).19,22,59 After a single oral voriconazole administration, the T1/2el was
longer in pigeons and African penguins, at 10.32 and 10.92 hours, respectively,
compared with other bird species (range, 0.90–2.29 hours), which presents the poten-
tial for drug accumulation with extended dosing.18–22,59 In pigeons, the administration
of 20 mg voriconazole/kg BW twice daily maintained plasma concentrations of greater
than the MIC of 500 ng/mL for 4 days, but induced hepatotoxicity.19,28 Furthermore,
voriconazole concentrations in the lung were only above the MIC in a few pigeons.19
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of voriconazole (10 mg/kg BW, once a day) for 20 to 30 days (see Table 2).28,59 Based
on these studies, the following dosing regimens have been suggested for voricona-
zole: pigeons, 10 mg/kg BW twice a day or 20 mg/kg once a day; chicken,
10 mg/kg BW once a day; Hispaniolan Amazon parrot, 18 mg/kg BW 3 times a day;
timneh gray parrot, 12 to 18 mg/kg BW twice a day; African penguin, 5 mg/kg once
a day; mallard duck, 20 mg/kg BW twice a day-3 times a day; and falcons,
12.5 mg/kg BW once or twice a day.18–22,54,59
On contrast with other azoles, fluconazole is highly water soluble. Consequently, the
drug can also be administered in the drinking water. Ratzlaff and colleagues47 demon-
strated that, by administering fluconazole-mediated drinking water at a concentration
of 100 mg/L for 8 days to cockatiels (Nymphicus hollandicus), fluconazole plasma con-
centrations could be maintained above the MIC for most strains of C albicans (based
on susceptibility data from humans). After oral administration of 10 mg fluconazole/kg
BW to cockatiels and timneh gray parrots, a similar relative bioavailability was
observed in both species; the area under the plasma concentration time curve was
149.28 versus 154.55 h$mg/mL, respectively. However, the maximum plasma concen-
tration was lower and the T1/2el longer in the cockatiel compared with timneh African
gray parrot (4.94 mg/mL vs 7.45 mg/mL, and 19.01 hours vs 9.22 hours, respec-
tively).21,47 Based on these studies, the following dosing regimens have been sug-
gested: cockatiels 5 to 10 mg/kg BW orally every 24 to 48 hours, drinking water
100 mg/L, and timneh gray parrots 10 to 20 mg/kg BW orally every 24 to 48 hours.
However, clinical studies are needed to verify the efficacy.
Beside the azoles, polyene macrolide antifungal agents are also frequently used in
avian medicine. Oral administration of amphotericin B is used widely to treat Macro-
rhabdus ornithogaster, at a recommended dosage of 25 to 100 mg/kg BW twice a
day.2 However, amphotericin B deoxycholate is amphipathic and exhibits low solubi-
lity and permeability, resulting in negligible absorption when administered orally.
Consequently, oral application to treat systemic aspergillosis is not recommended.6
Advances in drug delivery systems have overcome some of the solubility issues that
prevent oral bioavailability by improving drug stability in the GI tract environment,
providing opportunities for targeting specific sites in the GI tract, increasing drug sol-
ubility and bioavailability, and providing sustained release in the GI tract. However, un-
known in birds, poly(ethylene glycol)ylated PLGA NPs formulation of amphotericin B
increased the oral bioavailability of amphotericin B from 1.5% to 10.5% when
compared with the commercially available amphotericin B deoxycholate in rats by
increasing amphotericin B solubility.62 Similar to amphotericin, oral administration of
nystatin was shown to be effective in the treatment ofMornithogaster.2 A flock of bud-
gerigars was successfully treated with nystatin at 3,500,000 IU/L drinking water for
2 days, followed by 2,000,000 IU/L for 28 days.63
Terbinafine hydrochloride, an allylamine, can be given orally or topically. The admin-
istration of terbinafine hydrochloride (15 mg/kg, once a day) for 2 days in a multiple-
dose PK trial in African penguins provided plasma levels approaching the MIC of
1000 ng/mL against Aspergillus fumigatus (Table 3).64 Based on these PK parameters
of terbinafine, steady-state trough levels in African penguins are predicted to occur in
2 weeks at 1200 ng/mL, using 15 mg/kg BW once a day.64 Unfortunately, no PK pa-
rameters could be calculated after multiple oral administration of terbinafine in
red-tailed hawks (50–120 mg/kg BW; see Table 3), because most of the birds regur-
gitated within a few hours after administration.25 As a result, additional multiple dose
and clinical trials are needed to demonstrate the actual efficacy and safety of
long-term treatment with terbinafine against aspergillosis in birds.
Table 3
PK characteristics of terbinafine hydrochloride after single bolus and multiples doses administration in different bird species
Animal
Species BW (g)
Dosage
Terbinafine
Hydrochloride
(mg/kg BW)
Frequency of
Administration Feed
Cmin
(ng/mL) Tmax (h)
Cmax
(ng/mL)
Vd /F
(mL/kg) T1/2 (h)
Cl/F
(mL/h$kg)
Clung
(ng/g)
Cliver
(ng/g) Reference
PK oral
bolus
African
penguins
2700–3300 3 Single Yes — 2.70 100 37,000 — 867a — — Bechert
et al,64
2010
7 Single Yes — 1.60 200 37,000 — 633a — —
15 Single Yes — 2.40 200 68,000 — 933a — —
Red-tailed
hawks
1070–1670 15 Single No — 5.40 300 72,000 15.00 2300 — — Bechert
et al,25
2010
30 Single No — 3.40 1200 50,100 18.20 1400 — —
60 Single No — 5.10 2000 45,500 13.30 1400 — —
Hispaniolan
Amazon
parrot
274–329 60 Single Yes — 6.40 353 — 8.71 — — — Evans
et al,81
2013
Multiple
doses PK
African
penguins
2700–3300 15 SID, 4 d Yes 400 0.80 2100 — 16.00 500 — — Bechert
et al,64
2010
Red-tailed
hawks
1070–1670 120 SID, 2 d Yes — — — — — — — — Bechert
et al,25
2010
Day 1: 60;
d 2: 50
SID, 2 d Yes — — — — — — ND 270
Abbreviations: BW, bodyweight; Cl/F, clearance; Cliver, terbinafine concentration in liver; Clung, terbinafine concentration in lung; Cmax, maximum plasma concen-
tration; Cmin, minimal plasma terbinafine concentration inmultiple doses PK; F, absolute bioavailability; ND, not detected; PK, pharmacokinetic; SID, once a day; T1/
2el, elimination half-life; Tmax, time point of maximum plasma concentration; Vd or Vd/F, volume of distribution.
a Calculated based on average bodyweight.
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Inhalation is a very common technique of drug administration to patients with a variety
of lung diseases in humans. The treatment of respiratory fungal infections in avian
patients requires currently the use of oral or systemic agents; however, aerosolized
delivery (Fig. 1) is an attractive option because the lag time of the action onset of
the drug is short, less drug substance is needed, systemic side effects are reduced,
and nebulization is achieved with only minor patient stress.6,65 Pressurized metered
dose inhalers and dry powder inhalers systems might be difficult to use in avian pa-
tients because of practical difficulties. In contrast, nebulization is frequently used in
avian medicine, and administered to birds in a closed cage, induction chamber, or
by means of a face mask.43 Tell and colleagues66 showed that, with an increasing
time of exposure to aerosolized particles, the degree of particle deposition into the
avian respiratory system could be enhanced, until an equilibrium is established with
approximately uniform particle deposition/translocation to each of the air sacs of
the respiratory system.
Nebulizers convert a liquid in solution or suspension into small droplets. Two basic
types of nebulizers are frequently used, that is, the jet and the ultrasonic nebulizer. In
jet nebulizers, compressed air/oxygen passes through a capillary tube, trespasses the
entrained drug solution, and droplets suitable for inhalation are formed (Fig. 2). In an
ultrasonic nebulizer, an electronic oscillator generates a high-frequency ultrasonic
wave, and an aerosol is generated by the ultrahigh-frequency vibration of a piezoelec-
tric crystal at the bottom of a liquid (Fig. 3).65,67 Particles of the nebulized drug should
preferably have a mass median aerodynamic diameter between 1 and 5 mm, to reach
the lower respiratory tract, which is needed in case of aspergillosis.42,65 The newer
generation vibrating mesh nebulizers use electricity to vibrate a piezo element that
moves liquid formations through a fine mesh to generate aerosol.67 Mesh nebulizers
generate aerosols either passively with a transducer horn vibrating ultrasonically
against a static mesh or actively with a mesh mounted in an ultrasonically vibrating
piezo ring. These nebulizers have several distinct advantages over jet or ultrasonicFig. 1. Aerosol therapy in a cockatiel via a jet nebulizer. Nebulization is a drug delivery
method used to administer medication in the form of a mist (insert) inhaled into the respi-
ratory tract.
Fig. 2. Jet nebulizer working scheme. Compressed air/oxygen passes through a capillary
tube, trespasses the entrained drug solution, and droplets suitable for inhalation are
formed.
Fig. 3. Ultrasonic nebulizer working scheme. An electronic oscillator generates a high-
frequency ultrasonic wave, and an aerosol is generated by the ultrahigh- frequency vibra-
tion of a piezoelectric crystal at the bottom of a liquid.
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umes, minimizing drug loss to evaporation, a fast rate of nebulization, and the possi-
bility to nebulize a wider variability of drug compounds.68 Additionally, liposomes can
be delivered using a mesh and jet nebulizer, whereas an ultrasonic nebulizer is less
suitable for delivering these particles, because they only deposit a very small propor-
tion of phospholipids in the lower respiratory tract.67,69
Currently, there are no antifungal drugs on the market that have been developed
specifically to administer by nebulization. Consequently, in different avian studies
and clinical cases, birds are nebulized with the off-label use with antifungal drug
formulations that were developed for IV or oral administration. Nebulization of a
Hispaniolan Amazon parrot with terbinafine (crushed 250 mg terbinafine HCl tablet,
Camber Pharmaceuticals Inc, Piscataway, NJ; and raw terbinafine HCl powder)
dissolved in sterile water (1 mg/mL) for 15 minutes resulted in therapeutic plasma
concentrations (above MIC of A fumigatus and A fluvus) for 0.5 to 4.0 hours after
administration.70 However, because the lung levels were not assessed in this study,
clinical efficacy of this protocol in cases of avian aspergillosis still needs to be
elucidated.
After 15 minutes of nebulization of a commercially available IV formulation of vorico-
nazole (Vfend, Pfizer Global Pharmaceuticals, Ixelles, Belgium) dissolved in 0.9%NaCl
(10 mg/mL) with a jet nebulizer in pigeons, only low plasma and lung concentrations
(below the MIC of 0.5 mg/L) could be achieved for less than 1 hour.19 In contrast,
high and clinically relevant lung and plasma levels were found in mice after nebuliza-
tion with an aqueous solution of the IV voriconazole formulation (Vfend, 6.25 mg vor-
iconazole/mL in sterile water for injection, for 20 minutes) with an active mesh
nebulizer.71 In this study, the commercially available IV formulation was adjusted to
ensure that the osmolality (293.2 mOsm/kg) and pH (6.4–6.8) were within the physio-
logically acceptable ranges for pulmonary delivery by adding sulfobutylether-
b-cyclodextrin up to a concentration of 100mg/mL.71,72 The addition of this substance
helps to increase the water solubility of voriconazole in the commercial IV formulation
via complexation with sulfobutylether-b-cyclodextrin.73 Inhaled voriconazole signifi-
cantly improved the severity and survival of invasive pulmonary aspergillosis in mice
compared with control and treatment with intraperitoneal amphotericin B.72 Therefore,
the impact of adding extra sulfobutylether-b-cyclodextrin to the commercially avail-
able IV voriconazole formulation, and the use of a mesh nebulizer instead of a jet nebu-
lizer, on the PK/pharmacodynamic aspects of voriconazole aerosol therapy in birds
needs to be investigated.
In contrast with the older antifungal drug formulations, promising results are
observed when nebulizing antifungal NPs. A single intratracheal aerosol administration
of liposomal amphotericin B (AmBisome; 3 mg/kg BW) with a jet nebulizer in mallard
ducks resulted in drug concentrations above the MIC (1 mg/mL) in lung tissue for up to
9 days after administration. However, the drug distribution was uneven, with the ma-
jority of the drug concentrated in 1 lung lobe.33 Nebulized liposomal amphotericin B
showed an improved survival rate of rats with pulmonary aspergillosis compared
with animals treated with amphotericin deoxycholate IV.74 Similarly, once daily nebu-
lization with a 10% itraconazole NP suspension for 30 minutes was capable of allevi-
ating an acute A fumigatus infection in quails.75 High lung itraconazole concentrations,
well above the MIC for A fumigatus, were achieved after a single-dose inhalation of
itraconazole NP suspension (1% and 10% dissolved in distilled water with addition
of a 1.4% polysorbate 80 solution) to Japanese quails via a jet nebulizer for 30minutes.
Drug clearance from the lungs was slow, with a T1/2el of 19.7 and 35.8 hours after inha-
lation of 1% and 10% suspension, respectively. Even after 5-day repeated
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centrations were low (only 0.1% of the lung tissue concentration).76
In rare cases of fungal dermatologic infections in birds, the topical application of mi-
conazole, enilconazole, or clotrimazole might be used, whether or not combined with
systemic treatment.3,77 Oral candidiasis, which is most often seen in lorikeets and
associated with vitamin A deficiency, responds well to therapy with topical nystatin,
ketoconazole, fluconazole, miconazole, or itraconazole.78,79 Furthermore, wound
aspergillosis was successfully treated in a goliath heron (A goliath) with topical lipo-
somal amphotericin B, after well-established therapies with surgical debridement fol-
lowed by topical povidone-iodine in conjunction with oral itraconazole, and also
topical miconazole, failed.34
In conclusion, because the conventional treatment options have limitations such as
restricted efficacy, limited biodistribution, and toxicity, the use of newer antifungal
drug delivery methods should be considered by clinicians to overcome these limita-
tions and drawbacks in cases of treatment failure and toxicity.
SUMMARY
This review article aimed to provide insight into the interrelation of antifungal drug
formulation, administration route, therapeutic–toxic range, and treatment outcome
in fungal diseases, focusing in particular on aspergillosis in birds. The major antifungal
agents used in avian medicine are azole derivatives, polyenes, and allylamines, which
all owe their antifungal activities to inhibition of synthesis, or direct interaction with
ergosterol. Antifungal pharmacokinetics in birds are characterized by a large interspe-
cies and even interindividual variability. Consequently, conventional antifungal thera-
pies in avian medicine are frequently associated with a lack of efficacy and high
toxicity. Innovative drug formulations such as NPs can help to reduce the intrinsic
toxicity and enhance efficacy of antifungal agents in birds. Because the majority of
systemic fungal infections require long-term therapy, oral administration of antifungal
drugs is preferred, with IV administration being reserved for the initial phase of treat-
ment in cases of acute aspergillosis or severely debilitated birds. Finally, topical
administration of antifungals through nebulization shows promising results in birds;
however, because drug formulations and type of nebulizer are found to highly influ-
ence the therapeutic output, clinicians are recommended to take these factors into ac-
count when considering to use this administration route in their patients.
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